Biomedical company MolecularHealth‘s personalized TreatmentMAP technology for cancer patients was recently the main theme of the annual Hauptstadtkongress conference in Berlin, and reportedly impressed the medical community. With a CLIA-certified NGS lab located in Woodlands, Texas, the development of the system included collaboration from the University of Texas MD Anderson Cancer Center.
The CEO of MolecularHealth, Dr. Stephan Brock, stated that, “the classification of evidence from treatment of the individual patient is of great importance,” during the discussion and presentation platform of the conference dedicated to molecular medicine. He believes that physicians face this challenge, and that TreatmentMAP, a system that provides physicians with a custom tumor profile, will help them in the choice of a treatment, as well as an objective list of all available scientific and medical data that supports the decision.
“A small number of genetic changes can be sufficient for cancer to develop,” a rationale that has compelled experts to consider the need for a personalized approach to cancer treatment and consider the patient’s genetic cancer history to support their medical decisions, according to the director of the National Center for Tumor Diseases in Heidelberg, Dr. Christof von Kalle. Different patients, even if they suffer from the same type of cancer, suffer differently from the disease.
The director of the German Cancer Research Center, Dr. Otmar D. Wistler, explained in his opening speech at the conference that cancer is a genetic disease, and that this confirmation spurs on the development of new courses of diagnosis and treatment, such as TreatmentMAP. The definition of personal genome enables physicians to define a new set of more efficient therapeutic options, according to his speech.
The Federal Health Minister Hermann Gröhe also expressed his concern about assuring the quality of the healthcare and said he believes that technical developments like TreatmentMAP can make the difference as a guarantee of benefits like the effectiveness and better practice.
This is not the first time that TreatmentMAP has been presented at an international conference, since MolecularHealth was present, few days earlier, at this year’s American Association for Cancer Research (AACR) Precision Medicine Series Conference, in Orlando, where they highlighted the contribution of next-generation sequencing technology in the finding of evidence-based treatment strategies.
TreatmentMAP is a system that compares the personal data from a patient tumor’s genetic plan with biomedical knowledge and defined a profile of the cancer genome in order to evaluate the best individualized treatment. The device uses breakthrough sequencing data and enables physicians to provide patients with their molecular information, which is expected to result in more informed decisions as well as choices of medication.
Physicians who are trained and certified to use TreatmentMAP perform the sequencing of a tumor sample at a qualified sequencing laboratory, and integrate that information with the patient’s clinical data. The information is then examined at MolecularHealth, who in turn design the tumor profile. The report of the findings, including qualified and individualized recommendations of treatment, is done by the physician, based on the tumor profile.
MolecularHealth officially launched the system in May, after more than eight years in development by a multidisciplinary team of doctors, scientists, and IT experts, and is now planning a large-scale study to evaluate patients from all institutions with data from cancer types, as well as other factors such as age and metastasis status.